Further analysis showed that LY3039478 inhibits the Notch signaling pathway in ICC while inhibiting the expression of HES1, DLL4, VEGFA, and MMP13, confirming the significance and value of Notch signaling pathway inhibitors in ICC targeted therapy. Here, DLL4 is linked to intrahepatic cholangiocarcinoma.